DCM
KALV

Driehaus Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Driehaus Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-564,039
Closed -$11.4M – 399
2026
Q1 		$11.4M Buy
+564,039
New +$9.09M 0.08% 260
2024
Q3 		– Sell
-535,717
Closed -$6.31M – 420
2024
Q2 		$6.31M Sell
535,717
-5,821
-1% -$67.9K 0.06% 250
2024
Q1 		$6.42M Sell
541,538
-487,030
-47% -$6.49M 0.06% 267
2023
Q4 		$12.6M Sell
1,028,568
-6,055
-0.6% -$55.1K 0.15% 210
2023
Q3 		$9.96M Sell
1,034,623
-1,312
-0.1% -$13.4K 0.13% 208
2023
Q2 		$9.32M Buy
1,035,935
+20,816
+2% +$192K 0.12% 220
2023
Q1 		$7.98M Buy
1,015,119
+3,748
+0.4% +$28K 0.11% 246
2022
Q4 		$6.84M Buy
1,011,371
+481,932
+91% +$2.58M 0.1% 245
2022
Q3 		$7.68M Buy
+529,439
New +$7.4M 0.12% 227
2021
Q1 		– Sell
-50,000
Closed -$950K – 475
2020
Q4 		$950K Buy
+50,000
New +$857K 0.02% 327

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Driehaus Capital Management's KALV Position: Q2 2026 in Review

Driehaus Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 564,039 shares — an estimated $11.4M sold.

Driehaus Capital Management first reported a position in KALV in Q4 2020 and held it in 10 quarters. The position peaked at $12.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Driehaus Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Driehaus Capital Management sold 564,039 KalVista Pharmaceuticals shares in Q2 2026, an estimated $11.4M.
  • Driehaus Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Driehaus Capital Management's KalVista Pharmaceuticals position peaked at $12.6M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.